Several studies have identified ANXA10 as a tumor suppressor, diagnostic marker, potential therapeutic target, or prognostic factor in various malignancies, including bladder cancer, hepatocellular carcinoma, acute myeloid leukemia, gastric carcinoma, oral squamous cell carcinoma, pancreatobiliary adenocarcinoma, and urothelial carcinoma [33,34,35,36,37]. This evidence concerns the gene ANXA10 and acute myeloid leukemia.